123 results on '"Park, Jun Yong"'
Search Results
2. A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B
3. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
4. Identification of a distinct NK-like hepatic T-cell population activated by NKG2C in a TCR-independent manner
5. FRI-287 Increased risk of mortality in metabolic dysfunction-associated steatotic liver disease: a nationwide population-based cohort study
6. WED-456 Implementation of an Electronic Medical Record-Based Automatic Alert System for the Care Cascade of Hepatitis-C-Virus Infection in Patients Undergoing Elective Surgery
7. FRI-378 Effect of diabetes on the risk of fibrosis progression in patients with chronic hepatitis B
8. WED-269 Simultaneous assessment of skeletal muscle mass and handgrip strength to identify patients with NAFLD at high risk of advanced liver fibrosis
9. FRI-296 Metabolic dysfunction-associated steatotic liver disease and low handgrip strength are independently associated with a higher risk for cardiovascular disease
10. THU-292 Genome-wide association study identifies PTPRD associated with metabolic dysfunction-associated steatotic liver disease in South Korea
11. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
12. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea
13. Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells
14. Comparison of clinical outcome between Nivolumab and Regorafenib as second-line systemic therapy after Sorafenib failure in patients with advanced hepatocellular carcinoma
15. Low HBV DNA and HBsAg levels at 24 weeks off-treatment predict sustained response and HBsAg loss in patients who discontinued antiviral therapy
16. Aspirin use and risk of hepatocellular carcinoma and gastrointestinal bleeding in patients with HBV-related cirrhosis: a landmark analysis
17. Dickkopf-1 inhibitor enhances the anti-tumor effects of sorafenib through inhibition of PI3K/Akt/Wnt signaling in hepatocellular carcinoma
18. Screening, confirmation, and treatment rates of hepatitis C virus infections in patients undergoing surgery in a single tertiary academic centre
19. Morphological architectures of patient-derived hepatocellular carcinoma organoids with GSK3-beta expression dependent variability according to lenvatinib resistance
20. Erratum to ‘Identification of a distinct NK-like hepatic T-cell population activated by NKG2C in a TCR-independent manner’ [J Hepatol 77 (2022) 1059-1070]
21. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma
22. Patient-derived hepatocellular carcinoma organoids as predictors of Treatment Response
23. Predictors of HBsAg loss after cessation of nucleo (s)tide analogue therapy in asian patients with low HBsAg levels
24. Integrative clustering of multiple genomic data using organoid model with application to subtype analysis in intrahepatic cholangiocarcinoma
25. The therapeutic effect of Lactobacillus plantarum on metabolic phenotypes in non-alcoholic fatty liver disease mice model
26. Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels
27. WED-404 Comparable outcomes between Besifovir and other antiviral therapies in hepatocellular carcinoma development among patients with chronic hepatitis B
28. FRI-545 Dickkopf-1 inhibitor treated with sorafenib inhibited Wnt/PI3 K/Akt pathway in hepatocellular carcinoma
29. SAT-148 - Low HBV DNA and HBsAg levels at 24 weeks off-treatment predict sustained response and HBsAg loss in patients who discontinued antiviral therapy
30. WED-201 - Aspirin use and risk of hepatocellular carcinoma and gastrointestinal bleeding in patients with HBV-related cirrhosis: a landmark analysis
31. FRI-162 - Screening, confirmation, and treatment rates of hepatitis C virus infections in patients undergoing surgery in a single tertiary academic centre
32. THU-148 - Comparison of clinical outcome between Nivolumab and Regorafenib as second-line systemic therapy after Sorafenib failure in patients with advanced hepatocellular carcinoma
33. SAT-259 - Morphological architectures of patient-derived hepatocellular carcinoma organoids with GSK3-beta expression dependent variability according to lenvatinib resistance
34. FRI-387 - Dickkopf-1 inhibitor enhances the anti-tumor effects of sorafenib through inhibition of PI3K/Akt/Wnt signaling in hepatocellular carcinoma
35. Human liver CD8+ MAIT cells exert TCR/MR1-independent innate-like cytotoxicity in response to IL-15
36. Dickkopf-1 enhances tumourigenic potential by inducing liver angiogenesis
37. Evolution of hepatic fibrosis and steatosis during long-term use of metformin in patients with type 2 diabetes
38. Prognostic value of alpha-fetoprotein in patients achieving complete response to transarterial chemoembolisation for hepatocellular carcinoma
39. Guideline change for antiviral therapy reduced the risk of HBV-related HCC development among cirrhotic patients in South Korea
40. Low HBcrAg and HBsAg levels identify patients most likely to achieve sustained response after nucleos(t)ide analogue cessation: results from a global individual patient data meta-analysis (create study)
41. Advanced liver fibrosis predicts poor cardiovascular outcomes in patients with type 2 diabetes
42. A trans-activator of transcription-fusion bone morphogenetic protein 7 polypeptide suppresses CCL4 induced-hepatic fibrogenesis in mice
43. Association between curative treatment after transarterial radioembolization and better survival outcomes in patients with hepatocellular carcinoma
44. Combinatorial effect of ezetimibe and empagliflozin in non-alcoholic fatty liver disease in a mouse model and a liver organoid for disease modeling of hepatic steatosis
45. Empirical carbapenem versus third-generation cephalosporin treatment for spontaneous bacterial peritonitis: a multicenter study
46. Direct-acting antivirals improve treatment outcomes in patients with chronic hepatitis C-related hepatocellular carcinoma treated with transarterial chemoembolization: a nationwide, multi-center, retrospective cohort study
47. Functions of human liver CD69+CD103-CD8+ T cells depend on HIF-2α activity in healthy and pathologic livers
48. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance
49. FRI-216-Tenofovir monotherapy versus tenofovir plus entecavir combination therapy for multi-drug resistant chronic hepatitis B: Five year follow-up data of multicenter prospective cohort study (Final results)
50. THU-224-Validation of modified PAGE B in patients with chronic hepatitis B undergoing antiviral treatment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.